Prosecution Insights
Last updated: August 16, 2026

Sungkwang Medical Foundation

5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days

Portfolio Summary

5
Total Pending OAs
3
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (60%)
1
Medium (20%)
1
Easy (20%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (20%)
§103 only1 (20%)
§112 only1 (20%)
Multi-statute (no §101)2 (40%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
60% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
2
Mechanical / Eng
40% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
LULTSCHIK, WILLIAM G 1 22.4% +32.0%
JANG, CHRISTIAN Y 1 68.5% +21.0%
NGUYEN, NGHI V 1 53.4% +50.7%
WILSON, MICHAEL C 1 41.4% +17.5%
SALMON, KATHERINE D 1 42.6% +38.0%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
19127953 SERVER FOR AUTOMATICALLY DIAGNOSING MALE INFERTILITY, AND METHOD FOR DIAGNOSING MALE INFERTILITY BY USING SAME LULTSCHIK, WILLIAM G
18264521 METHOD FOR DIFFERENTIATING PLURIPOTENT STEM CELL-DERIVED HEMOGENIC ENDOTHELIAL CELLS INTO LYMPHOID LINEAGE CELLS WILSON, MICHAEL C
17780946 BIOMARKERS FOR PREDICTING THERAPEUTIC RESPONSIVENESS TO IMMUNE THERAPEUTIC AGENT SALMON, KATHERINE D

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18556783 MESENCHYMAL STEM CELLS HAVING ENHANCED OSTEOGENIC DIFFERENTIATION CAPACITY, AND USE THEREOF NGUYEN, NGHI V 28d overdue
19127953 SERVER FOR AUTOMATICALLY DIAGNOSING MALE INFERTILITY, AND METHOD FOR DIAGNOSING MALE INFERTILITY BY USING SAME LULTSCHIK, WILLIAM G
18846979 METHOD FOR PROVIDING FETUS MONITORING SERVICE AND SERVER FOR PERFORMING SAME JANG, CHRISTIAN Y
18264521 METHOD FOR DIFFERENTIATING PLURIPOTENT STEM CELL-DERIVED HEMOGENIC ENDOTHELIAL CELLS INTO LYMPHOID LINEAGE CELLS WILSON, MICHAEL C
17780946 BIOMARKERS FOR PREDICTING THERAPEUTIC RESPONSIVENESS TO IMMUNE THERAPEUTIC AGENT SALMON, KATHERINE D

Top Art Units

Art UnitApps
3682 1
3796 1
1653 1
1638 1
1682 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19127953 SERVER FOR AUTOMATICALLY DIAGNOSING MALE INFERTILITY, AND METHOD FOR DIAGNOSING MALE INFERTILITY BY USING SAME LULTSCHIK, WILLIAM G 3682 §101§103 Non-Final OA Pending Aug 29, 2025
18846979 METHOD FOR PROVIDING FETUS MONITORING SERVICE AND SERVER FOR PERFORMING SAME JANG, CHRISTIAN Y 3796 §112 Non-Final OA Pending Sep 13, 2024
18556783 MESENCHYMAL STEM CELLS HAVING ENHANCED OSTEOGENIC DIFFERENTIATION CAPACITY, AND USE THEREOF NGUYEN, NGHI V 1653 §103 Final Rejection 28d overdue Pending Oct 23, 2023
18264521 METHOD FOR DIFFERENTIATING PLURIPOTENT STEM CELL-DERIVED HEMOGENIC ENDOTHELIAL CELLS INTO LYMPHOID LINEAGE CELLS WILSON, MICHAEL C 1638 §103§112 Final Rejection Pending Aug 07, 2023
17780946 BIOMARKERS FOR PREDICTING THERAPEUTIC RESPONSIVENESS TO IMMUNE THERAPEUTIC AGENT SALMON, KATHERINE D 1682 §103§112 Non-Final OA Pending May 27, 2022

Managing Sungkwang Medical Foundation's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month